Oncoinvent ASA · OSL:ONCIN
Oncoinvent ASA — Investor Presentation (February 2023)
23 slides from Oncoinvent ASA's investor presentation, Feb 17, 2023
Slide 1: Company Presentation
Company Presentation 17. February 2023 Jan A. Alfheim CEO 1
Slide 2: A Global Leader in Alpha-Emitting Radiotherapeutics
A Global Leader in Alpha-Emitting Radiotherapeutics Oncoinvent is advancing a pipeline of radiopharmaceutical products across a variety of solid cancers that leverages robust internal R&D and manufacturing capabilities to enable a clinical supply of radioisotopes 2
Slide 3: Oncoinvent has built a company for the creation of next generation radiopharmaceuticals
Oncoinvent has built a company for the creation of next generation radiopharmaceuticals We are one of the few companies that has a demonstrated expertise in the discovery, clinical development, and manufacturing of radiopharmaceuticals Radiochemistry and Innovative clinical Robust isotope Clinical s
Slide 4: Radspherin®
Radspherin® Innovative alpha particle-based radiopharmaceutical therapy for cancer patients Radspherin® description Designed for precise and safe impact Strong biodistribution results to date Specifically designed to safely deliver precise Imaging of clinical trial subjects indicates that there A su
Slide 5: First Indication: Peritoneal Carcinomatosis (PC)
First Indication: Peritoneal Carcinomatosis (PC) Poor survival rates for patients with PC • Cancer of the peritoneum is often the result of the Five-year survival rates in ovarian cancer* metastatic spread of cancer cells from pre-existing cancer. 90% 70% The most common cancers that cause peritonea
Slide 6: Treating Patients with Radspherin®
Treating Patients with Radspherin® 1. Complete surgical removal (CRS) of the peritoneal tumours 2. Radspherin® Administration 1-2 days Malignant ascites is a serious condition commonly post- operative related to PC Radspherin intraperitoneal injection through indwelling catheter, by nuclear medicine
Slide 7: Radspherin® - clinical studies
Radspherin® - clinical studies Two Phase I/2A studies ongoing • RAD-18-001: following complete surgical resection in patients with platinum sensitive recurrent epithelial ovarian/fallopian tube cancer with peritoneal carcinomatosis • Oslo/Norway(PI: Yun Wang) • Leuven, Belgium (PI: Els van Nieuwenhu
Slide 8: Radspherin® - clinical studies status
Radspherin® - clinical studies status 3.5 RAD-18-002 Repeated R Injection cohort, 2 x 3,5MBq Expansion Cohort RAD-18-001; n=20, FU 24 months RAD-18-002; n=30 FU 18 months RAD-18-002/RAD-18-001 Expansion cohort With Dosimetry 7MBq RAD-18-002 RAD-18-001 n= 32/53 patients recruited n= 16/32 patients re
Slide 9: Radspherin® clinical trial status
Radspherin® clinical trial status RAD-18-001 (ovarian cancer patients with PC ) • Recruitment of the dose range study was completed (1, 2, 4 & 7 MBq dose levels) in December • Both clinical sites (Radium Hospital & KU Leuven) are participating in the expansion cohort • Two additional sites in Spain
Slide 10: Radspherin® clinical trial status
Radspherin® clinical trial status RAD-18-002 (colorectal cancer patients with PC) • Preliminary safety data presented at ASCO in June • Efficacy signal at 12 months noted • Phase 2A started 25th of August • Both clinical sites (Radium Hospital and Uppsala) are recruiting patients 10
Slide 11: Robust Safety Profile Seen to Date
Robust Safety Profile Seen to Date Robust safety profile seen to date with minor side effects reported ✓ Well tolerated and considered safe to • No dose limiting toxicities observed at any dose level • Absorbed doses to normal organs well below dose levels associated with toxicity use ✓ Clinically r
Slide 12: RAD-18-002 - first indications of clinical efficacy
RAD-18-002 - first indications of clinical efficacy • Expected median time to progression based on published literature* is 10-12 months in comparable patient populations receiving CRS plus HIPEC therapy • Meaning that 50 % of patients are expected to have recurred at 10 - 12 months • In the cohort
Slide 13: Comparison of percent recurrence rates CRS-HIPEC versus CRS-HIPEC & Radspherin
Comparison of percent recurrence rates CRS-HIPEC versus CRS-HIPEC & Radspherin 60 50 40 30 52,1 53,9 41,0 20 25 10 0 OUS CRS+ HIPEC 10 MONTHS, N= 119 PRODIGE 7 CRS+HIPEC 12 MONTHS, N=133 PRODIGE 7 CRS ALONE 12 MONTHS, N= RAD-18-002 CLINICALLY RELEVANT DOSE 132 (7MBQ) 12 MONTHS, N=12 OUS CRS + HIPEC:
Slide 14: Preliminary recurrence rate data from RAD-18-002 at 12 months
Preliminary recurrence rate data from RAD-18-002 at 12 months All dose groups: • Recurrence rate (n=23) : 9/23 (39%) with progression • Peritoneal recurrence rate (n=21*): 4/21 (19%) with progression Recommended dose 7 MBq: • Recurrence rate (n=12): 3/12 (25%) with progression • Peritoneal recurrenc
Slide 15: RAD-18-001 - first indications of clinical efficacy
RAD-18-001 - first indications of clinical efficacy • Expected recurrence rates of around 30 % at 12 months based on published literature in comparable patient population • 12-month timepoint reached for most patients enrolled in study to date • Recurrence rates at 12 months • At dose levels 1, 2, 4
Slide 16: Radspherin® Clinical Development Plan
Radspherin® Clinical Development Plan* Indication 2022 2023 2024 2025 2026 Ovarian cancer Recurrent Phase 1 12 mo (n=13) 12 mo (n=37) + population 18mo(n=15) Primary Phase 2 population Pivotal Colorectal Phase 1/2a 12 mo (n=53)+ 18mo (n=23) 12 mo 15 mo 18 mo (n=23) (n=23) (n=23) Phase 2 Pivotal * Di
Slide 17: Oncoinvent's Vibrant and Promising Development Pipeline
Oncoinvent’s Vibrant and Promising Development Pipeline Discovery Preclinical Phase I Description Target Peritoneal carcinomatosis RAD-18-001: Radspherin® Alpha-emitting from ovarian cancer radioactive microspheres designed for treatment of metastatic cancers in Peritoneal carcinomatosis RAD-18-002:
Slide 18: CD146 - function and tumor expression
CD146 - function and tumor expression CD146 has been shown to be actively involved in various processes, such as development, signalling transduction, cell migration, mesenchymal stem cells differentiation, endothelial signalling, angiogenesis and immune response. CD146 is found to be upregulated in
Slide 19: Internalization of OI-3
Internalization of OI-3 Time % OI-3-Al488 Cell Antibody point internalized 45 min 14,4 45 min 23,4 Cetuximab 4h 31,2 4h 45,2 OHS 45 min 37,7 OI-3-Al488 followed by 45 min 49,1 OI-3 stripping of surface 4h 50,2 bound 4h 51,6 Assay with lead-212 labeled antibodies Microscopy, 2 h incubation 19
Slide 20: Last private placement of USD 25 M
Last private placement of USD 25 M • The proceeds were designed to allow company to move both Radspherin clinical studies into phase 2a • The proceeds were also targeted to allow the start of development of a targeted radiotherapeutic in 2022 • In total Oncoinvent has raised over USD 55 million 20
Slide 21: Financial status Q4-2022
Financial status Q4-2022 KEY FIGURES 4th QUARTER YTD (AMOUNTS IN NOK thousand) 2022 2021 2022 2021 • EBITDA result in Q4-2022 of minus TOTAL REVENUES AND OTHER INCOME 5 541 6 520 6 283 11 083 NOK 32.9 mill. (~USD 3.3 mill.) Payroll and related expenses -17 229 -12 460 -50 970 -38 310 • Invest in pro
Slide 22: Anticipated Milestones for 2023
Anticipated Milestones for 2023 • Publication of 15-month data from phase 1 colorectal study at ASCO • Publication of 18-month data from phase 1 colorectal study • Publication of preclinical studies on OI-3 targeted radiotherapeutic • Development of new targeted radiopharmaceutical agent • Completio
Slide 23: On~o
On~o Invent